ScFv-based, EGFR-targeted CAR-T cells have shown some efficacy in various types of solid tumors, including triple-negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), multiple glioblastoma (GBM), and ESCC [49,50,51,52]. This evidence concerns the gene EGFR and triple-negative breast carcinoma.